Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Huda A. Al-Taee"'
Publikováno v:
Iraqi Journal of Hematology, Vol 9, Iss 2, Pp 72-76 (2020)
BACKGROUND: The use of BCR-ABL tyrosine kinase inhibitor imatinib mesylate improved outcomes for patients with chronic myeloid leukemia (CML). Hypophosphatemia is found to be associated with imatinib mesylate use; the exact mechanism of this is not c
Externí odkaz:
https://doaj.org/article/c2be39b10c5a404887aa19e5bcad191a
Publikováno v:
Experimental and Clinical Transplantation. 20:299-305
Objectives Organ donation is the driving force for transplant. Awareness about donation and transplant is invaluable for improved transplant services in any country. Our objective was to assess the knowledge and attitude toward organ donation and tra
Publikováno v:
Full Text Book of Minar Congress 7.
Plants produced for their beauty rather than their practical utility are known as ornamental plants. There are several sorts of attractive plants such as Rubber, Gladiolus, Iris, and others. Fungi impacting these plants were isolated and identified u
Publikováno v:
Nephrology Dialysis Transplantation
Background and Aims Renal transplant recipients seems at particular risk for Coronavirus disease 2019 (COVID-19). In addition to immune suppression cessation, multiple therapies have been tried with no supportive evidence. Favipiravir and colchicine
Publikováno v:
Journal of Nephropathology.
Crescentic glomerulonephritis (GN) is a severe proliferative renal lesion with an aggressive clinical scenario. The occurrence of crescentic GN post-transplant is mainly related to the recurrence of the primary glomerular disease. De novo crescentic
Publikováno v:
La Prensa Medica Argentina. 106
Autor:
Ala Ali, Huda A Al-Taee
Publikováno v:
Transplantation. 104:S294-S294
Publikováno v:
Iraqi Journal of Hematology, Vol 9, Iss 2, Pp 72-76 (2020)
BACKGROUND: The use of BCR-ABL tyrosine kinase inhibitor imatinib mesylate improved outcomes for patients with chronic myeloid leukemia (CML). Hypophosphatemia is found to be associated with imatinib mesylate use; the exact mechanism of this is not c